Why the study?
What are the key findings from the EMOTE, HERB-CHF, BEST genetic Sub-Study, and RHYTHM-ICD trials presented at the Heart Failure Society of America annual meeting?
What are the key findings from the EMOTE, HERB-CHF, BEST genetic Sub-Study, and RHYTHM-ICD trials presented at the Heart Failure Society of America annual meeting?
This review highlights key heart failure trial updates, showing potential benefits for enoximone in severe HF, pharmacogenomic targeting with bucindolol, and CRT for symptom improvement, while hawthorn extract lacked efficacy.
Recent HF trial data remain hypothesis-generating; larger prospective studies needed to validate before practice change.
This article summarises key presentations relevant to the pathophysiology, prevention or treatment of heart failure, from the Heart Failure Society of America annual meeting held in Toronto, Canada. Data from the EnoxiMone in intravenous inOTropE-dependent subjects (EMOTE) study suggest that the oral PDE-3 inhibitor enoximone may be effective for weaning severe heart failure patients from intravenous inotropic therapy. Hawthorn Extract Randomised Blinded Trial in CHF (HERB-CHF) failed to show a benefit of hawthorn extract added to conventional heart failure therapy. A genetic sub-group analysis of the Blocker Evaluation of Survival Trial (BEST) study showed that bucindolol reduced mortality and hospitalisations in patients who were homozygous for the Arg389 variant of the beta(1) adrenoceptor. In the Resynchronisation Hemodynamic Treatment for Heart Failure Management (RHYTHM-ICD) study, patients randomised to cardiac resynchronisation therapy (CRT) showed an improvement in symptoms and functional capacity compared to the control group.
No takes yet. Share an insight, caveat, or question.
Lalukota et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: